ArticleInternational scholarly research notices2014
Yaws Prevalence, Lessons from the Field and the Way Forward towards Yaws Eradication in Ghana.
Article in International scholarly research notices, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- A Single Dose Oral Azithromycin versus Intramuscular Benzathine Penicillin for the Treatment of Yaws-A Randomized Non Inferiority Trial in Ghana.PLoS neglected tropical diseases · 2017Trial
- Evidence based targeting of districts for active surveillance of skin-related neglected tropical diseases in Ghana.PLOS global public health · 2026Article
- Mapping the distribution of yaws and Haemophilus ducreyi in the western north region of Ghana.BMC infectious diseases · 2025Observational
- Seroprevalence and geospatial epidemiology of yaws: Evidence from Ghana.PLoS neglected tropical diseases · 2025Article
- Yaws in Africa: Past, Present and Future.Diseases (Basel, Switzerland) · 2025Review
- Detection of cutaneous leishmaniasis in three communities of Oti Region, Ghana.PLoS neglected tropical diseases · 2021Article
- Factors associated with cutaneous ulcers among children in two yaws-endemic districts in Ghana.Infectious diseases of poverty · 2020Article
- Community-based mass treatment with azithromycin for the elimination of yaws in Ghana-Results of a pilot study.PLoS neglected tropical diseases · 2018Article
- Yaws resurgence in Bankim, Cameroon: The relative effectiveness of different means of detection in rural communities.PLoS neglected tropical diseases · 2017Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Despite past WHO/UNICEF led global yaws eradication efforts, the disease seems to persist. The true burden is however not known for comprehensive action. Ghana's data showed significant increase in notified cases since the 1970s. Recognizing limitations in routine data, we carried out a yaws treatment survey in 2008 in three purposively selected districts to establish the prevalence and learn lessons for renewed action. Of 208,413 school children examined, 4,006 were suspected yaws cases (prevalence 1.92 (95% CI: 1.86-1.98) percent). Of 547 schools surveyed, 13% had prevalence between 5% and 10% while 3% had prevalence above 10%. The highest school prevalence was 19.5%. Half of the schools had cases. The large sample allowed aggregating the school results by administrative levels. The lowest aggregated prevalences of 0.23%, 0.40%, and 0.64% were in the urban sub-districts of Asamankese, Oda, and Achiase, respectively, while the highest of 8.61%, 3.69%, and 1.4% were in rural Akroso, Mepom, and Aperade, respectively. In conclusion, the prevalence of yaws is high in some schools in rural, hard-to-reach areas of Ghana. Considering past global eradication efforts, our findings suggest yaws may be resurging for which programmatic action is needed.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.